
AGTC
Healthcare · Biotechnology · $26.6M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2022
EPS trend, 90 days to now · -24.1% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 21, 2022 | After the close | -0.28 | -0.28 | 0.0% |
| Sep 27, 2022 | After the close | -0.34 | -0.36 | -5.9% |
| May 16, 2022 | After the close | -0.43 | -0.33 | +23.3% |
| Feb 14, 2022 | Before the open | -0.38 | -0.45 | -18.4% |
| Nov 9, 2021 | Before the open | -0.35 | -0.40 | -14.3% |
| Sep 23, 2021 | After the close | -0.40 | -0.28 | +30.0% |
| May 17, 2021 | After the close | -0.41 | -0.40 | +2.4% |
| Feb 11, 2021 | Before the open | -0.59 | -0.60 | -1.7% |
| Nov 16, 2020 | After the close | -0.53 | -0.60 | -13.2% |
| Sep 9, 2020 | Before the open | -0.48 | -0.56 | -16.7% |
| May 13, 2020 | Before the open | -0.55 | -0.50 | +9.1% |
| Feb 5, 2020 | After the close | -0.61 | -0.47 | +23.0% |
| Nov 12, 2019 | After the close | -0.60 |
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical…
| -0.64 |
| -6.7% |
| Sep 26, 2019 | After the close | -0.54 | -0.58 | -7.4% |
| May 7, 2019 | Before the open | -0.58 | 0.63 | +208.6% |
| Feb 7, 2019 | Before the open | -0.68 | -0.23 | +66.2% |
| Nov 8, 2018 | Before the open | -0.39 | 0.07 | +117.9% |
| Sep 10, 2018 | After the close | -0.17 | -0.37 | -117.6% |
| May 8, 2018 | After the close | -0.41 | -0.45 | -9.8% |
| Feb 9, 2018 | Before the open | -0.19 | -0.29 | -52.6% |